Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Conformational Dynamics of Sclerostin-LRP6 Complex Analyzed by HDX-MS

  • Jeong, Yejing (School of Pharmacy, Sungkyunkwan University) ;
  • Kim, Jinuk (Department of Biological Sciences, Seoul National University) ;
  • Choi, Hee-Jung (Department of Biological Sciences, Seoul National University) ;
  • Chung, Ka Young (School of Pharmacy, Sungkyunkwan University)
  • Received : 2020.12.29
  • Accepted : 2021.03.22
  • Published : 2021.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

Sclerostin (SOST), a regulator of bone formation in osteocytes, inhibits the canonical Wnt signaling by interacting with low-density lipoprotein receptor-related protein 5/6 (LRP5/6) to prevent Wnt binding. Loss-of-function mutations of the SOST gene caused massive bone outgrowth and SOST-null mouse exhibited a high bone density phenotype. Therefore, SOST has been suggested as a promising therapeutic target for osteoporosis. A few previous studies with X-ray crystallography identified the binding interfaces between LRP6 and SOST, but there are limitations in these studies as they used truncated SOST protein or SOST peptide. Here, we analyzed the conformational dynamics of SOST-LRP6 E1E2 complex using hydrogen/deuterium exchange mass spectrometry (HDX-MS). We examined the effect of the C-terminal tail of SOST on LRP6 conformation upon complex formation. HDX-MS analysis suggested a new potential binding interface for the C-terminal region of SOST that was missing from the previous crystal structure of the SOST-LRP6 E1E2 complex.

Keywords

Acknowledgement

This research is supported by the National Research Foundation of Korea, funded by the Korean government (grant numbers NRF-2018R1A2B6001554 and NRF-2019R1A5A2027340 to K.Y.C. and NRF-2020R1A2C2003783 to H.-J.C.).

References

  1. Ahn, V. E., Chu, M. L., Choi, H. J., Tran, D., Abo, A. and Weis, W. I. (2011) Structural basis of Wnt signaling inhibition by Dickkopf binding to LRP5/6. Dev. Cell 21, 862-873. https://doi.org/10.1016/j.devcel.2011.09.003
  2. Balemans, W., Ebeling, M., Patel, N., Van Hul, E., Olson, P., Dioszegi, M., Lacza, C., Wuyts, W., Van Den Ende, J., Willems, P., PaesAlves, A. F., Hill, S., Bueno, M., Ramos, F. J., Tacconi, P., Dikkers, F. G., Stratakis, C., Lindpaintner, K., Vickery, B., Foernzler, D. and Van Hul, W. (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10, 537-543. https://doi.org/10.1093/hmg/10.5.537
  3. Bourhis, E., Tam, C., Franke, Y., Bazan, J. F., Ernst, J., Hwang, J., Costa, M., Cochran, A. G. and Hannoush, R. N. (2010) Reconstitution of a frizzled8.Wnt3a.LRP6 signaling complex reveals multiple Wnt and Dkk1 binding sites on LRP6. J. Biol. Chem. 285, 9172-9179. https://doi.org/10.1074/jbc.M109.092130
  4. Bourhis, E., Wang, W., Tam, C., Hwang, J., Zhang, Y., Spittler, D., Huang, O. W., Gong, Y., Estevez, A., Zilberleyb, I., Rouge, L., Chiu, C., Wu, Y., Costa, M., Hannoush, R. N., Franke, Y. and Cochran, A. G. (2011) Wnt antagonists bind through a short peptide to the first beta-propeller domain of LRP5/6. Structure 19, 1433-1442. https://doi.org/10.1016/j.str.2011.07.005
  5. Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y., Alisch, R. S., Gillett, L., Colbert, T., Tacconi, P., Galas, D., Hamersma, H., Beighton, P. and Mulligan, J. (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68, 577-589. https://doi.org/10.1086/318811
  6. Cheng, Z., Biechele, T., Wei, Z., Morrone, S., Moon, R. T., Wang, L. and Xu, W. (2011) Crystal structures of the extracellular domain of LRP6 and its complex with DKK1. Nat. Struct. Mol. Biol. 18, 1204-1210. https://doi.org/10.1038/nsmb.2139
  7. DeBruine, Z. J., Xu, H. E. and Melcher, K. (2017) Assembly and architecture of the Wnt/beta-catenin signalosome at the membrane. Br. J. Pharmacol. 174, 4564-4574. https://doi.org/10.1111/bph.14048
  8. Giladi, M., Lee, S. Y., Hiller, R., Chung, K. Y. and Khananshvili, D. (2015) Structure-dynamic determinants governing a mode of regulatory response and propagation of allosteric signal in splice variants of Na+/Ca2+ exchange (NCX) proteins. Biochem. J. 465, 489-501. https://doi.org/10.1042/BJ20141036
  9. Holdsworth, G., Slocombe, P., Doyle, C., Sweeney, B., Veverka, V., Le Riche, K., Franklin, R. J., Compson, J., Brookings, D., Turner, J., Kennedy, J., Garlish, R., Shi, J., Newnham, L., McMillan, D., Muzylak, M., Carr, M. D., Henry, A. J., Ceska, T. and Robinson, M. K. (2012) Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors. J. Biol. Chem. 287, 26464-26477. https://doi.org/10.1074/jbc.M112.350108
  10. Kim, J., Han, W., Park, T., Kim, E. J., Bang, I., Lee, H. S., Jeong, Y., Roh, K., Kim, J., Kim, J. S., Kang, C., Seok, C., Han, J. K., Choi, H. J. (2020) Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains. Nat. Commun. 11, 5357. https://doi.org/10.1038/s41467-020-19155-4
  11. Lewiecki, E. M. (2011) Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. Expert Opin. Biol. Ther. 11, 117-127. https://doi.org/10.1517/14712598.2011.540565
  12. Li, X., Ominsky, M. S., Niu, Q. T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., Asuncion, F., Barrero, M., Warmington, K., Dwyer, D., Stolina, M., Morony, S., Sarosi, I., Kostenuik, P. J., Lacey, D. L., Simonet, W. S., Ke, H. Z. and Paszty, C. (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 23, 860-869. https://doi.org/10.1359/jbmr.080216
  13. Lintern, K. B., Guidato, S., Rowe, A., Saldanha, J. W. and Itasaki, N. (2009) Characterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals. J. Biol. Chem. 284, 23159-23168. https://doi.org/10.1074/jbc.M109.025478
  14. MacNabb, C., Patton, D. and Hayes, J. S. (2016) Sclerostin antibody therapy for the treatment of osteoporosis: clinical prospects and challenges. J. Osteoporos. 2016, 6217286.
  15. Nolan, K., Kattamuri, C., Luedeke, D. M., Deng, X., Jagpal, A., Zhang, F., Linhardt, R. J., Kenny, A. P., Zorn, A. M. and Thompson, T. B. (2013) Structure of protein related to Dan and Cerberus: insights into the mechanism of bone morphogenetic protein antagonism. Structure 21, 1417-1429. https://doi.org/10.1016/j.str.2013.06.005
  16. Semenov, M., Tamai, K. and He, X. (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 280, 26770-26775. https://doi.org/10.1074/jbc.M504308200
  17. Semenov, M. V. and He, X. (2006) LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J. Biol. Chem. 281, 38276-38284. https://doi.org/10.1074/jbc.M609509200
  18. Veverka, V., Henry, A. J., Slocombe, P. M., Ventom, A., Mulloy, B., Muskett, F. W., Muzylak, M., Greenslade, K., Moore, A., Zhang, L., Gong, J., Qian, X., Paszty, C., Taylor, R. J., Robinson, M. K. and Carr, M. D. (2009) Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J. Biol. Chem. 284, 10890-10900. https://doi.org/10.1074/jbc.M807994200
  19. Winkler, D. G., Sutherland, M. K., Geoghegan, J. C., Yu, C., Hayes, T., Skonier, J. E., Shpektor, D., Jonas, M., Kovacevich, B. R., Staehling-Hampton, K., Appleby, M., Brunkow, M. E. and Latham, J. A. (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22, 6267-6276. https://doi.org/10.1093/emboj/cdg599